Updated:
China National Traditional Chinese Medicine
Founded in 1987 and headquartered in Beijing's Haidian District, China National Traditional Chinese Medicine Co., Ltd. operates as the dedicated Traditional...
China National Traditional Chinese Medicine
Founded in 1987 and headquartered in Beijing's Haidian District, China National Traditional Chinese Medicine Co., Ltd. operates as the dedicated Traditional Chinese Medicine (TCM) platform under the state-owned China National Pharmaceutical Group (Sinopharm). The firm is publicly listed on the Hong Kong Stock Exchange under the ticker 0570.HK, though a significant going-private proposal initiated in 2024 signals a structural shift that would fully remove it from public markets. The entity consolidates the production, distribution, and retail of Chinese herbal medicines and related pharmaceutical products under a single operational umbrella. The firm's deployment footprint covers the entire TCM value chain, an approach that distinguishes it from pure-play pharmaceutical manufacturers. Its asset base includes more than 20 intelligent distribution centers, dedicated seed and seedling breeding bases, and core industrial production facilities spread across 22 mainland Chinese provinces. The product portfolio spans concentrated herbal granules, Chinese patent medicines, and herbal decoction pieces. An in-house TCM Quality Traceability System, covering raw material sourcing through finished goods, supports the firm's regulated supply chain. Beyond physical products, the firm is extending into e-commerce and medical healthcare services to capture patient-facing distribution channels. The company's corporate structure is defined by its relationship to Sinopharm, China's largest pharmaceutical group, which functions as the ultimate controlling shareholder. A consortium including the China State-Owned Enterprise Mixed Ownership Reform Fund, Advanced Manufacturing Industry Investment Fund Phase II, and China Reform Development Investment Management joined Sinopharm Common Wealth Company Limited to submit a take-private proposal in 2024, an operational event that reshapes its governance trajectory. A Hong Kong administrative office at Emperor Group Centre supplements the Beijing headquarters. The firm participates in industry standard-setting through its membership in the China Association of Traditional Chinese Medicine. What sets the firm apart structurally is its role as a policy-aligned industrial consolidator rather than a pure financial investor. Unlike Western pharmaceutical enterprises that separate R&D, manufacturing, and distribution, Sinopharm's TCM unit vertically integrates seed-to-patient control, positioning itself to enforce quality standards dictated by the China Pharmacopoeia. The 2024 privatization effort, driven by state-backed reform funds, suggests Beijing intends to accelerate consolidation in the fragmented TCM sector without the disclosure constraints of a public listing.
General information
Firm type
Corporate Investor
Year founded
1987
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
No 20 Zhichun Road, Haidian District, Beijing, China
Additional offices
Room 1601, 288 Hennessy Road, Wan Chai, Hong Kong
Principals
China National Pharmaceutical Group (Sinopharm)
Ultimate controlling shareholder
Sector focus
Frequently asked questions
Who controls China National Traditional Chinese Medicine?
The ultimate controlling shareholder is the China National Pharmaceutical Group (Sinopharm), a large state-owned enterprise administered by the State-owned Assets Supervision and Administration Commission (SASAC) of China's State Council. Sinopharm exerts control through its direct and indirect equity holdings in the company.
What is the status of the take-private transaction?
In February 2024, the company announced that Sinopharm Common Wealth Company Limited, acting in concert with several state-backed co-investors, proposed a voluntary conditional general offer to acquire all issued shares and cancel the listing on the Hong Kong Stock Exchange. The consortium offered HK$4.6 per share, implying an equity valuation of approximately HK$15.5 billion. Completion is subject to regulatory approvals and acceptance thresholds.
How does the firm's TCM Quality Traceability System work?
The firm operates a proprietary quality traceability system that spans the entire production chain, from the geographic origin and cultivation of raw herbs at its seed and seedling breeding bases through manufacturing at its industrial plants and final distribution through intelligent logistics centers. This system is designed to comply with national Good Manufacturing Practice standards and align with China's regulatory push for a unified TCM material traceability framework.
What is the firm's geographic production footprint?
The firm's industrial production and distribution infrastructure covers 22 provinces and municipalities across mainland China. Its operational assets include dedicated seed and seedling facilities, large-scale TCM manufacturing bases, and more than 20 intelligent distribution centers. A secondary administrative office is maintained in Hong Kong's Emperor Group Centre.
Is China National Traditional Chinese Medicine a pharmaceutical company or an industrial consolidator?
While it generates revenue from manufacturing and selling Chinese patent medicines and herbal granules, the firm functions structurally as an industrial consolidator for China's fragmented TCM sector. The Sinopharm parent relationship and the post-2024 privatization suggest the entity serves as a state-backed platform to modernize and vertically integrate TCM assets rather than operating as a conventional pharmaceutical commercialization vehicle.
Which external funds participate in the company's privatization consortium?
The privatization consortium includes the China State-Owned Enterprise Mixed Ownership Reform Fund, the Advanced Manufacturing Industry Investment Fund Phase II, and China Reform Development Investment Management. These state-affiliated reform funds are acting in concert with Sinopharm Common Wealth Company Limited to take the firm private, indicating Beijing's active role in restructuring this TCM platform.
What is the firm's relationship to the China Association of Traditional Chinese Medicine?
The company is a leading member of the China Association of Traditional Chinese Medicine, an industry body that participates in setting standards for the sector. This membership complements the firm's operational role as a quality-driven, vertically integrated manufacturer aligned with national pharmacopoeia standards.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: